Food OIT is Superior to Food Avoidance

Over the last decade much attention has focused on the possibility of using oral immunotherapy (OIT) as a therapeutic approach for treatment of IgE-mediated food allergies, a disease without a Food and Drug Administration (FDA)-approved disease-modifying therapy. Peanut allergy has been a particular concern because of its persistent nature and association with potentially life-threatening reactions. The OIT literature has been criticized for heterogeneity in trial design with disparities in identification of allergic individuals by double blind placebo controlled food challenges (DBPCFC), differences in desensitization approaches and maintenance doses of allergen, absence of a standardized product, inconsistency in the primary endpoint (e.g.

https://ift.tt/2qI49fL